申请人:Elf Sanofi
公开号:US05403933A1
公开(公告)日:1995-04-04
The invention relates to indolizine derivatives of general formula: ##STR1## in which: X denotes an --S or --SO.sub.2 -- group, each of R.sub.1 and R.sub.2, which are identical or different, denotes hydrogen, the methyl or ethyl radical or a halogen atom, R.sub.3 denotes hydrogen or a C.sub.1 -C.sub.4 alkyl radical, R.sub.4 denotes a precursor radical of a carboxyl group, R denotes a C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl or phenyl radical, and their use as intermediates for the preparation of pharmaceutically active aminoalkoxybenzenesulphonylindolizine derivatives.
该发明涉及一般式为:##STR1##的吲哚啉衍生物,其中:X代表--S或--SO.sub.2--基团,R.sub.1和R.sub.2分别代表相同或不同的氢、甲基或乙基基团或卤素原子,R.sub.3代表氢或C.sub.1-C.sub.4烷基基团,R.sub.4代表羧基的前体基团,R代表C.sub.1-C.sub.6烷基、C.sub.3-C.sub.6环烷基或苯基,以及它们作为制备具有药用活性的氨基烷氧基苯磺酰吲哚啉衍生物的中间体的用途。